Cargando…

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis

The aim of this study was to evaluate the effect of denosumab (Dmab) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of Dmab in bisphosphonate-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sánchez, A., Brun, L. R., Salerni, H., Costanzo, P. R., González, D., Bagur, A., Oliveri, B., Zanchetta, M. B., Farías, V., Maffei, L., Premrou, V., Mansur, J. L., Larroudé, M. S., Sarli, M. A., Rey, P., Ulla, M. R., Pavlove, M. M., Karlsbrum, S., Brance, M. L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4992763/ https://www.ncbi.nlm.nih.gov/pubmed/27579211 http://dx.doi.org/10.1155/2016/8738959

Ejemplares similares

Effect of Teriparatide on Bone Mineral Density and Bone Markers in Real-Life: Argentine Experience
por: Guelman, Rodolfo, et al.
Publicado: (2023)

Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment
por: Brun, Lucas R, et al.
Publicado: (2014)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial
por: McClung, M. R., et al.
Publicado: (2012)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients
por: Hori, Mayuko, et al.
Publicado: (2022)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

High bone turnover elevates the risk of denosumab-induced hypocalcemia in women with postmenopausal osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2016)

Multicentric carpotarsal osteolysis syndrome (MCTO) with generalized high bone turnover and high serum RANKL: Response to denosumab
por: Regev, Ravit, et al.
Publicado: (2021)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Relationships between Bone Turnover and Energy Metabolism
por: Fernandes, Tânia A. P., et al.
Publicado: (2017)

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Denosumab for Prevention of Acute Onset Immobilization‐Induced Alterations of Bone Turnover: A Randomized Controlled Trial
por: Wadiura, Lisa Irina, et al.
Publicado: (2022)

Bone turnover predicts change in volumetric bone density and bone geometry at the radius in men
por: Pye, S. R., et al.
Publicado: (2016)

Metabolomic Associations with Serum Bone Turnover Markers
por: Bellissimo, Moriah P., et al.
Publicado: (2020)

Malignant Transformation of Giant Cell Tumor of Bone and the Association with Denosumab Treatment: A Radiology and Pathology Perspective
por: van Langevelde, K., et al.
Publicado: (2022)

Amelioration of Paget Disease of Bone After Denosumab for Osteopenia
por: Kamalumpundi, Vijayvardhan, et al.
Publicado: (2023)

Raloxifene Has No Efficacy in Reducing the High Bone Turnover and the Risk of Spontaneous Vertebral Fractures after Denosumab Discontinuation
por: Gonzalez-Rodriguez, Elena, et al.
Publicado: (2018)

Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study
por: Palmerini, Emanuela, et al.
Publicado: (2022)

Circulating markers of bone turnover
por: Vervloet, Marc G., et al.
Publicado: (2017)

Bone turnover in elderly men: relationships to change in bone mineral density
por: Nguyen, Tuan V, et al.
Publicado: (2007)

Use of Denosumab in Children With Osteoclast Bone Dysplasias: Report of Three Cases
por: Upfill‐Brown, Alexander, et al.
Publicado: (2019)

Radiological findings of denosumab treatment for giant cell tumours of bone
por: van Langevelde, Kirsten, et al.
Publicado: (2020)

Long Term Cyclic Pamidronate Reduces Bone Growth by Inhibiting Osteoclast Mediated Cartilage-to-Bone Turnover in the Mouse
por: Evans, K.D, et al.
Publicado: (2008)

Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change
por: Nakatoh, Shinichi
Publicado: (2017)

Bone microarchitecture and bone turnover in hepatic cirrhosis
por: Wakolbinger, R., et al.
Publicado: (2019)

Effects of competitive physical activity on serum irisin levels and bone turnover markers
por: Gaudio, A., et al.
Publicado: (2021)

Assessment of bone turnover and bone quality in type 2 diabetic bone disease: current concepts and future directions
por: Rubin, Mishaela R, et al.
Publicado: (2016)

Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extension.
por: Berruti, A., et al.
Publicado: (1996)

Sclerostin as a novel marker of bone turnover in athletes
por: Zagrodna, A, et al.
Publicado: (2016)

Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases
por: Generali, D, et al.
Publicado: (2008)

FRI685 Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases
por: Patil, Madhuri D, et al.
Publicado: (2023)

Impact of denosumab on bone mass in cancer patients
por: Brown-Glaberman, Ursa, et al.
Publicado: (2013)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Laboratory reproducibility of biochemical markers of bone turnover in clinical practice
por: Schafer, A. L., et al.
Publicado: (2009)

High bone turnover status as a risk factor in symptomatic hypocalcemia following denosumab treatment in a male patient with osteoporosis
por: Ishikawa, Koji, et al.
Publicado: (2018)

Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE
por: Eastell, R., et al.
Publicado: (2019)

Effect of Denosumab Compared With Risedronate on Bone Strength in Patients Initiating or Continuing Glucocorticoid Treatment
por: Geusens, Piet, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_pc2ijib218rvrnnbg4nphcj55c